🇺🇸 FDA
Pipeline program

Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

PRO-PCV-1001

Phase 1 mab completed

Quick answer

Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine for Pneumococcal Infections is a Phase 1 program (mab) at SINOVAC BIOTECH LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
SINOVAC BIOTECH LTD
Indication
Pneumococcal Infections
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials